Monoclonal antibodies binding platinum complexes

• US 5,053,226 A
• Filed: 07/15/1987
• Issued: 10/01/1991
• Est. Priority Date: 07/15/1987
• Status: Expired due to Fees

• Current Assignee: Board of Regents of the University of Texas System (University of Texas System)
• Original Assignee: Board of Regents of the University of Texas System (University of Texas System)
• Inventors: Murray, James L., Newman, Robert A., Rosenblum, Michael G., Khokhar, Abdul R., Kelleher, Peter J.
• Primary Examiner(s): Richter, Johann
• Application Number:
  US07/073,500
• Time in Patent Office: 1,539 Days
• Field of Search: 435/240.26, 435/240.27, 424/85.8
• US Class Current: 530/388.9
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 47/6879 the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
• CPC Class Codes: C07K 16/44 against material not provided for elsewhere , e.g. haptens, metals, DNA, RNA, amino acids
• CPC Class Codes: C07K 16/468 Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies

Abstract

The present invention relates to monoclonal antibodies specifically binding platinum (II) complex. The monoclonal antibodies of the present invention are characteristically produced by antibody-producing cell lines such as hybridomas. These cell lines may result, for example, from fusion of a neoplastic cell with an antibody-producing animal cell obtained from an animal immunized against a platinum (II) complex. The cellular fusion products include cell lines forming monoclonal antibody specifically binding platinum (II) complex in competition with an antibody produced by: hybridoma strain 1C₁ H₂ A₅, deposited with the American Type Culture Collection, Rockville, MD on May 1, 1987 and having ATCC accession number HB 9411; strain 3A₂ A₁ ; strain 1A₆ A₂ ; strain 3A₆ B₁ or strain 1B₁. The cell lines of the present invention are preferably continuous murine hybridoma cell lines which secrete recoverable quantities of monoclonal antibody, particularly a monoclonal antibody which is of an IgG or IgM isotype.

Claims

1. A cell line resulting from fusion of a neoplastic cell with an antibody-producing animal cell obtained from an animal immunized against a platinum (II) complex, said cell line forming a monoclonal antibody specifically binding platinum (II) complex in competition with an antibody produced by hybridoma strain 1C₁ H₂ A₅ having ATCC accession number HB 9411, strain 3A₂ A₁, strain 1A₆ A₂, strain 3A₆ B₁ or strain 1B₁.

2. The cell line of claim 1 defined further as being a continuous murine hybridoma cell line which secretes recoverable quantities of monoclonal antibody.

3. The cell line of claim 1 wherein the monoclonal antibody is of an IgG or IgM isotype.

4. The cell line of claim 1 wherein the neoplastic cell is a myeloma cell.

5. The cell line of claim 1 wherein the antibodyproducing animal cell is a splenic cell.

6. The cell line of claim 1 wherein the animal is immunized with a conjugate of a platinum (II) complex and a macromolecular species.

7. The cell line of claim 6 wherein the macromolecular species is a polynucleotide.

8. The cell line of claim 7 wherein the polynucleotide is DNA.

9. The cell line of claim 7 wherein the macromolecular species is a protein.

10. The cell line of claim 1 defined further as being hybridoma strain 1C₁ H₂ A₅ having ATCC accession number HB 9411, strain 3A₂ A₁, strain 1A₆ A₂, strain 3A₆ B₁ or strain 1B₁.

11. The cell line of claim 1 wherein the platinum (II) complex is a DACH-platinum (II) complex.

12. A murine hybridoma cell line producing recoverable quantities of a monoclonal antibody which specifically binds a platinum (II) complex.

13. The murine hybridoma cell line of claim 12 wherein the monoclonal antibody is of an IgG or IgM isotype.

14. The murine hybridoma cell line of claim 12 defined further as produced by a process involving immunization of a mouse against platinum (II) complex coupled to a carrier and fusion of antibody-producing cells from said animal with a neoplastic murine cell line.

15. The murine hybridoma cell line of claim 12 wherein the platinum (II) complex is a DACH-platinum (II) complex.

16. A composition of matter comprising a monoclonal antibody specifically binding a platinum (II) complex.

17. The composition of matter of claim 16 wherein the monoclonal antibody is defined further as binding a platinum (II) complex in competition with an antibody produced by hybridoma strain 1C₁ H₂ A₅ having ATCC accession number HB 9411, strain 3A₂ A₁, strain 1A₆ A₂, strain 3 A₆ B₁ or strain 1B₁.

18. The composition of matter of claim 16 wherein the monoclonal antibody is defined further as being an antibody produced by hybridoma strain 1C₁ H₂ A₅ having ATCC accession number HB 9411, strain 3A₂ A₁, strain 1A₆ A₂, strain 3A₆ B₁ or strain 1B₁.

19. The composition of matter of claim 16 wherein the monoclonal antibody is defined further as being of an IgG or IgM isotype.

20. The composition of matter of claim 16 wherein the platinum (II) complex is a DACH-platinum (II) complex.